Investigating how genetic diversity in tumors affects chemotherapy resistance in leukemia
Developing Bioinformatic and Microfluidic Single Cell Methods for Studying Intratumoral Heterogeneity in Acute Myeloid Leukemia
This study is looking at how different types of cancer cells in acute myeloid leukemia (AML) can affect how well chemotherapy works, with the hope of finding better, more personalized treatment options for patients based on their specific tumor characteristics.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10533290 on NIH RePORTER |
What this research studies
This research focuses on understanding how the diversity of tumor cells within acute myeloid leukemia (AML) can influence resistance to chemotherapy. By utilizing advanced bioinformatic and microfluidic techniques, the study aims to analyze single cells to uncover the relationship between intratumoral heterogeneity and treatment outcomes. Patients may benefit from insights that could lead to more effective, personalized treatment strategies based on the unique genetic makeup of their tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who are undergoing or have undergone chemotherapy.
Not a fit: Patients with other types of leukemia or those who are not receiving chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with acute myeloid leukemia by identifying specific tumor characteristics that predict chemotherapy resistance.
How similar studies have performed: Other research has shown promising results in understanding tumor heterogeneity and its impact on treatment resistance, suggesting that this approach could yield valuable insights.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Paguirigan, Amy — Fred Hutchinson Cancer Center
- Study coordinator: Paguirigan, Amy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.